Zacks Investment Research
21 May 2026, 15:40 UTC · 5h ago
Source · https://www.zacks.com/stock/news/2924824/atra-stock-shoots-up-82-in-a-month-here-s-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-analyst_blog|price_surge_/_plunge-2924824
Read source
Search tags
Story key points
3 claims · impact-rated
The FDA agreed that a single-arm study using a historical control could provide sufficient safety and efficacy data for the future marketing application of tab-cel. — This removes a significant regulatory hurdle by providing a clear, agreed-upon pathway to approval for a drug addressing a high unmet medical need.
+0.60Atara's partner, Pierre Fabre Pharmaceuticals, intends to submit an updated dataset with additional patients and longer follow-up from the phase III ALLELE study. — The submission of updated data is a necessary step toward resubmission, though it does not guarantee approval.
+0.30Atara expects to provide the next regulatory update regarding the tab-cel BLA resubmission in the third quarter of 2026. — This indicates a long timeline before the next major catalyst, which may lead to a period of stagnation or volatility for the stock.
-0.10Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
Shares rallied over 80% following a positive FDA update regarding a path forward for its lead product candidate.
No ticker relationship head found.
